Business / Finance RSS Feed - Business / Finance

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Eli Lilly and Company and Adocia today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. [More]
Aviv REIT acquires 28 properties for $305 million from Diamond Senior Living

Aviv REIT acquires 28 properties for $305 million from Diamond Senior Living

Aviv REIT, Inc. announced today that it acquired 28 properties (plus an office building) for $305 million from Diamond Senior Living, LLC, a subsidiary of General Electric Credit Corporation of Tennessee (itself a subsidiary of General Electric Capital Corporation). [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma. [More]

Intronix Technologies, Western University collaborate to develop rehabilitation devices

Intronix Technologies will be collaborating with Western University's Department of Electrical and Computer Engineering to develop technology to be incorporated into rehabilitation devices. [More]
VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, today announced that they have signed a multi-year software licence and support agreement with existing alliance partner, IXICO plc, the brain health company, for their proprietary imaging data and query management digital platform, TrialTracker™. [More]
Sophia Genetics earns ISO 13485 and ISO 27001 certification for safe data handling and security

Sophia Genetics earns ISO 13485 and ISO 27001 certification for safe data handling and security

Sophia Genetics, the European leader in Clinical Genomics and Next Generation DNA Sequencing (NGS), has become the first company to achieve both ISO 13485 and ISO 27001 certification for its commitment to safe data handling and security. [More]

Novasep expands presence in South East Asia with opening of new office in Thailand

Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand. [More]
Endomagnetics reveals new brand identity Endomag

Endomagnetics reveals new brand identity Endomag

Endomagnetics is revealing a new brand identity that accurately reflects its position as a global leader in the development of devices for cancer care based on the application of advanced magnetic technologies. [More]
Anavex Life Sciences qualifies to trade on OTCQX

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies. [More]
Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians. [More]
Champions reports decrease in revenue for second quarter of 2015

Champions reports decrease in revenue for second quarter of 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014. [More]
HudsonAlpha buys Illumina HiSeq X Ten sequencing system

HudsonAlpha buys Illumina HiSeq X Ten sequencing system

HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care. [More]
Abbott acquires control of Veropharm for $305 million

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. [More]
Claritas, NextCODE Health partner to bring global leadership in pediatric medicine, sequence analysis

Claritas, NextCODE Health partner to bring global leadership in pediatric medicine, sequence analysis

To rapidly expand the use and power of genomic sequencing for diagnosing and treating rare diseases, Claritas Genomics and NextCODE Health today announced a strategic partnership bringing together global leadership in pediatric medicine and sequence analysis. Claritas Genomics, affiliated with Boston Children's Hospital, is a CLIA-certified clinical laboratory serving the DNA-based diagnostic testing needs of children's hospitals that admit hundreds of thousands of patients with genetic disorders every year. [More]
GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners today announced that it has completed the acquisition of 9911 Belward Campus Drive located in Rockville, Maryland. The acquisition was made through TechCore, LLC, which is a $1 billion discretionary core real estate fund managed by GI Partners. [More]
Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

Diplomat, the nation's largest independent specialty pharmacy, has announced a new partnership with Novation through their Hospital Specialty Rx Program. [More]
Plymouth University receives £1.2M in funding to support capital investment for teaching facilities

Plymouth University receives £1.2M in funding to support capital investment for teaching facilities

Plymouth University has received funding in excess of £1.2M from the Higher Education Funding Council for England to support capital investment for teaching facilities in existing and proposed laboratories, at the headquarters of Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), Plymouth Science Park. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B. [More]